Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Anavex Life Sciences (AVXL)
NASDAQ:AVXL
RESEARCH TOOLSreports
Holding AVXL?
Track your performance easily
AVXL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.25 - $10.45
Previous Close$8.69
Volume28.34K
Average Volume (3M)1.18M
Market Cap
$735.18M
Enterprise Value$598.12M
Total Cash (Recent Filing)$138.76M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.89
Next Earnings
Dec 23, 2024EPS Estimate
-$0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding84,795,517
10 Day Avg. Volume1,335,675
30 Day Avg. Volume1,181,795
Standard Deviation0.25
R-Squared0.02
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)5.68
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-37.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-12.40
Forecast
1Y Price Target
$27.50Price Target Upside217.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Anavex Life Sciences News
Bulls Say, Bears Say
Bulls Say
Regulatory ProgressEncouraging feedback from European regulators indicates they could prove receptive to granting market authorization to Anavex's lead candidate blarcamesine.
Safety ProfileBlarcamesine’s safety profile indicates that its use would not require routine MRI monitoring to detect anomalies indicating brain edema or bleeding.
Therapeutic EfficacyBlarcamesine showed numerically superior clinical efficacy to approved agents while also slowing neurodegeneration in early Alzheimer's disease patients.
Bears Say
Patient RetentionConcerns were raised around the drop out rate prior to treatment initiation.
Study ReliabilityThe large error bars are also a function of smaller cohort size.
Treatment ContinuationHigh discontinuation rate in first 24 weeks of treatment—31% of patients discontinued treatment due to AEs.
---
Ownership Overview
3.05% Insiders
8.56% Mutual Funds
4.27% Other Institutional Investors
71.32% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AVXL FAQ
What was Anavex Life Sciences’s price range in the past 12 months?
Anavex Life Sciences lowest stock price was $3.25 and its highest was $10.45 in the past 12 months.
What is Anavex Life Sciences’s market cap?
Currently, no data Available
When is Anavex Life Sciences’s upcoming earnings report date?
Anavex Life Sciences’s upcoming earnings report date is Dec 23, 2024 which is in 4 days.
How were Anavex Life Sciences’s earnings last quarter?
Anavex Life Sciences released its earnings results on Aug 06, 2024. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.16 by $0.02.
Is Anavex Life Sciences overvalued?
According to Wall Street analysts Anavex Life Sciences’s price is currently Undervalued.
Does Anavex Life Sciences pay dividends?
Anavex Life Sciences does not currently pay dividends.
What is Anavex Life Sciences’s EPS estimate?
Anavex Life Sciences’s EPS estimate is -$0.16.
How many shares outstanding does Anavex Life Sciences have?
Anavex Life Sciences has 84,795,520 shares outstanding.
What happened to Anavex Life Sciences’s price movement after its last earnings report?
Anavex Life Sciences reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.16. Following the earnings report the stock price went up 5.736%.
Which hedge fund is a major shareholder of Anavex Life Sciences?
Among the largest hedge funds holding Anavex Life Sciences’s share is Deerfield Management Company, LP. It holds Anavex Life Sciences’s shares valued at 599K.
---
Anavex Life Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$27.50 (217.19% Upside)
$27.50 (217.19% Upside)
Blogger Sentiment
Bullish
AVXL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 8.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 12.4%
Last 30 Days ▲ 12.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.13%
12-Months-Change
Fundamentals
Return on Equity
-30.03%
Trailing 12-Months
Asset Growth
-10.26%
Trailing 12-Months
Company Description
Anavex Life Sciences
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
---
AVXL Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook with significant advancements in clinical trials and a strong financial position. Despite increased R&D expenses and challenges in trial data collection, the company is well-positioned to continue its progress in Alzheimer's, schizophrenia, and Parkinson's programs.Read More>---
AVXL Stock 12 Month Forecast
Average Price Target
$27.50
▲(217.19% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Cassava Sciences
―
Bioxcel Therapeutics
―
Intra-Cellular Therapies
―
Best Analysts Covering AVXL
1 Year
1 Year Success Rate
16/27 ratings generated profit
1 Year Average Return
+89.47%
initiated a buy rating 5 months ago
Copying Jason Kolbert's trades and holding each position for 1 Year would result in 59.26% of your transactions generating a profit, with an average return of +89.47% per trade.
---